浮针治疗膝骨关节炎的随机对照研究

注册号:

Registration number:

ITMCTR2200006055

最近更新日期:

Date of Last Refreshed on:

2022-06-03

注册时间:

Date of Registration:

2022-06-03

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

浮针治疗膝骨关节炎的随机对照研究

Public title:

A randomized controlled study of floating needle in the treatment of knee osteoarthritis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

浮针治疗膝骨关节炎的随机对照研究

Scientific title:

A randomized controlled study of floating needle in the treatment of knee osteoarthritis

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200060511 ; ChiMCTR2200006055

申请注册联系人:

李佩泽

研究负责人:

贺君

Applicant:

PeiZe Li

Study leader:

Jun He

申请注册联系人电话:

Applicant telephone:

18814090285

研究负责人电话:

Study leader's telephone:

13728020800

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lipeize@stu.gzucm.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

895150145@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广州市白云区机场路12号

研究负责人通讯地址:

广州市白云区机场路12号

Applicant address:

No. 12, Jichang Road, Baiyun District, Guangzhou

Study leader's address:

No. 12, Jichang Road, Baiyun District, Guangzhou

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州中医药大学

Applicant's institution:

Guangzhou University of traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

K-2022-044

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

广州中医药大学第一附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of Guangzhou University of traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

1990/1/1 0:00:00

伦理委员会联系人:

黎欣盈

Contact Name of the ethic committee:

XinYing Li

伦理委员会联系地址:

广州市白云区机场路16号

Contact Address of the ethic committee:

No. 16, Jichang Road, Baiyun District, Guangzhou

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广州中医药大学第一附属医院

Primary sponsor:

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

广东省广州市白云区机场路16号

Primary sponsor's address:

16 Airport Road, Baiyun District, Guangzhou, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州中医药大学第一附属医院

具体地址:

白云区机场路16号

Institution
hospital:

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

Address:

16 Airport Road, Baiyun District

经费或物资来源:

广东省中医针灸重点实验室开放课题项目

Source(s) of funding:

Open project of Guangdong Key Laboratory of traditional Chinese medicine and acupuncture

研究疾病:

膝骨关节炎

研究疾病代码:

Target disease:

Knee osteoarthritis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

本课题在经筋理论指导下以浮针疗法治疗膝关节骨性关节炎,采用大样本、多中心随机对照试验,与康复治疗进行对照研究,并借助三维步态、肌骨超声、X线检查等客观指标,评估浮针疗法治疗膝关节炎的疗效与安全性,优化治疗方案,提高疗法的精准性,形成浮针治疗KOA的诊疗规范,并为临床应用提供强有力的循证医学证据。

Objectives of Study:

Under the guidance of Jingjin theory, this subject uses floating needle therapy to treat knee osteoarthritis. Large sample, multi center randomized controlled trials are used to conduct a comparative study with rehabilitation therapy. With the help of objective indicators such as three-dimensional gait, muscle bone ultrasound and X-ray examination, the efficacy and safety of floating needle therapy in the treatment of knee osteoarthritis are evaluated, the treatment scheme is optimized, the accuracy of the therapy is improved, and the diagnosis and treatment specification of floating needle therapy for koa is formed, And provide strong evidence-based medical evidence for clinical application.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合美国风湿病学会关于膝关节炎的诊断标准,经X线片证实者; (2)符合Kellgren-Lawrecne的放射学诊断标准中的I、II、III级患者; (3)年龄在40-80岁之间,性别不限; (4)1周内未服用其他相关治疗药物或采用相关治疗方法者(长期服用药物者,需停用药物1周后方可纳入观察); (5)自愿参加,并签署知情同意书,愿意接受试验。

Inclusion criteria

(1) Those who meet the diagnostic criteria of the American rheumatic Society for knee arthritis and are confirmed by X-ray films; (2) Grade I, II and III patients meeting the radiological diagnostic criteria of Kellgren lawrecne; (3) Between 40-80 years old, regardless of gender; (4) Those who have not taken other relevant drugs or adopted relevant treatment methods within 1 week (those who have taken drugs for a long time need to stop taking drugs for 1 week before they can be included in the observation); (5) Volunteer to participate, sign the informed consent form, and be willing to accept the test.

排除标准:

(1)孕妇或者患有重大疾病、传染病者; (2)膝关节有骨折、脱位、结核、肿瘤、感染等病史者(本类患者病情可能对所观察到的治疗结果产生影响); (3)对本试验中所涉及的医疗器械(如浮针)等过敏者; (4)精神类疾病,无自制力,不能确切表达者; (5)试验前3个月参加过其他临床试验者; (6)文化水平太低,无法理解试验或量表内容。

Exclusion criteria:

(1) Pregnant women or persons suffering from major diseases or infectious diseases; (2) Patients with a history of fracture, dislocation, tuberculosis, tumor, infection, etc. in the knee joint (the condition of such patients may affect the observed treatment results); (3) Those who are allergic to the medical devices (such as floating needles) involved in this test; (4) Mental illness, lack of self-control, unable to express accurately; (5) Those who participated in other clinical trials 3 months before the trial; (6) The educational level is too low to understand the contents of the test or scale.

研究实施时间:

Study execute time:

From 2021-09-01

To      2023-09-30

征募观察对象时间:

Recruiting time:

From 2022-05-24

To      2023-09-30

干预措施:

Interventions:

组别:

治疗组

样本量:

44

Group:

Treatment group

Sample size:

干预措施:

浮针

干预措施代码:

Intervention:

Floating needle

Intervention code:

组别:

对照组

样本量:

44

Group:

Control group

Sample size:

干预措施:

康复

干预措施代码:

Intervention:

Rehabilitation technique

Intervention code:

样本总量 Total sample size : 88

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东省

市(区县):

广州市

Country:

China

Province:

Guangdong

City:

单位(医院):

广州中医药大学第一附属医院

单位级别:

三甲医院

Institution/hospital:

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

三维步态

指标类型:

次要指标

Outcome:

Three dimensional gait

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

X线

指标类型:

次要指标

Outcome:

X-ray

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

WOMAC骨关节炎指数

指标类型:

主要指标

Outcome:

WOMAC Osteoarthritis Index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肌骨超声

指标类型:

次要指标

Outcome:

Musculoskeletal ultrasound

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

VAS评分

指标类型:

次要指标

Outcome:

VAS score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 40
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

统计软件用 Stata14.0软件包,按1:1的比例,用分层区组随机化的方法产生随机数。分层方式按Kellgren-Lawrence X线分级标准分为三层,区组大小为6个。随机数由与本试验无关的人员对治疗方案进行分配编码,并用不透光的信封进行密封保存,相关资料密封后,交由临床研究负责单位及本试验注册申请人分别保存。

Randomization Procedure (please state who generates the random number sequence and by what method):

Stata14.0 software package was used for statistical software, and random numbers were generated by stratified block randomization in the ratio of 1:1. According to the Kellgren Lawrence X-ray grading standard, the stratification method is divided into three layers, and the size of the block is 6. The random&#32

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

数据库

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

database

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统